Cite
HARVARD Citation
Morelli, A. et al. (n.d.). 1404PSafety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. Annals of oncology. p. . [Online].